- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00967928
Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
13. února 2014 aktualizováno: Accelerated Community Oncology Research Network
Phase I Everolimus Dose Finding Study for the Treatment of Stage IV or Recurrent, Non-resectable, Cervical Cancer With Standard Whole Pelvic Radiation Therapy in Combination With Weekly Cisplatin and Daily Everolimus
This Phase 1, single-site, dose-escalation study is being conducted to determine the maximum tolerated dose (MTD) of RAD001 as part of a specified combination regimen.
Přehled studie
Postavení
Staženo
Podmínky
Intervence / Léčba
Detailní popis
This Phase 1, single-site, dose-escalation study is being conducted to determine the MTD of RAD001 as part of a specified combination regimen.
The combination regimen will be standard field whole pelvic RT in combination with cisplatin at 40mg/m2 weekly with RAD001 at dose escalation daily starting at 5 mg qod, then 5 mg qd, then 10 mg qd during the period of whole pelvic radiation therapy.
Typ studie
Intervenční
Fáze
- Fáze 1
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let a starší (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Ženský
Popis
Inclusion Criteria:
- Patients must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors criteria that has not been previously irradiated.
- Female patient aged ≥18 years.
- Patient has life expectancy of at least 12 weeks at study start.
- Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study start.
- Patient has diagnosis of stage IV or recurrent, non-resectable, cervical cancer at study start.
- Patient has received no prior chemotherapy.
Patient has adequate hematologic function:
- Absolute neutrophil count [ANC] ≥1500/μL
- Platelets ≥100,000/μL
- Hemoglobin > 9g/dL
Patient has adequate renal function:
- Serum creatinine ≤ 2.0 mg/dL
- Calculated creatinine clearance ≥ 50 mL/min
Patient has adequate hepatic function:
- Serum bilirubin ≤1.5 x ULN
- ALT and AST ≤2.5 × ULN (≤ 5 x ULN in patients with liver metastases)
- INR <1.5 (or < 3 on anticoagulants)
- Patient has fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN.
- Patient is able to provide signed informed consent.
Exclusion Criteria:
- Patient has neuroendocrine or small cell carcinoma of the cervix.
- Patient has previously used any biologic therapy with VEGF, VEGFR, or ErbB1/ErbB2 inhibitors.
- Patient is currently receiving anticancer therapies or has received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.).
- Patient has had a major surgery or significant traumatic injury within 4 weeks of start of study drug; patient has not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patient might require major surgery during the course of the study.
- Patient has had prior treatment with any investigational drug within the preceding 4 weeks before study start.
- Patient is receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
- Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period. Patients should also avoid close contact with people who have received live vaccines during treatment with everolimus. Examples of live vaccines are: intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, and TY21a typhoid vaccines.
- Patient has known brain or leptomeningeal metastases.
- Patient has had other malignancies within the past 3 years except for adequately treated squamous cell carcinomas of the skin.
Patients has any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
- Symptomatic congestive heart failure of New York Heart Association Class III or IV.
- Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.
- Severely impaired lung function defined as spirometry and diffusing capacity (DLCO) that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air.
- Uncontrolled diabetes as defined by fasting serum glucose >1.5 × ULN.
- Active (acute or chronic) or uncontrolled severe infections.
- Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
- Patient has a known history of human immunodeficiency virus seropositivity.
- Patient has impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
- Patient has an active, bleeding diathesis.
- Female patient who is pregnant or breast feeding, or an adult of reproductive potential who is not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial and for up to 8 weeks after ending treatment by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001.)
- Patient has received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).
- Patient has a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients.
- Patient has history of noncompliance to medical regimens.
- Patient is unwilling to or unable to comply with the protocol.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Single arm
All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
|
RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
Ostatní jména:
Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks.
The preferred administration day is Monday.
Ostatní jména:
Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
To determine the maximum tolerated dose for RAD001 as adjunct therapy to standard upfront treatment of advanced stage cervical cancer in combination with weekly cisplatin and whole pelvic external beam radiation
Časové okno: every 7 days
|
every 7 days
|
To determine the dose limiting toxicities for RAD001 as adjunct therapy to standard upfront treatment of advanced stage cervical cancer in combination with weekly cisplatin and whole pelvic external beam radiation
Časové okno: every 7 days
|
every 7 days
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
To determine the pharmacokinetics of RAD001 given as adjunct therapy to standard upfront treatment of advanced stage cervical cancer
Časové okno: day 1 and day 15 during study treatment
|
day 1 and day 15 during study treatment
|
To evaluate the pharmacogenetics of RAD001 in the specified patient population
Časové okno: day 1 prior to starting study treatment
|
day 1 prior to starting study treatment
|
To evaluate microvessel density pre-and post-treatment with the specified treatment regimen in the specified patient population
Časové okno: day 1 and end of treatment
|
day 1 and end of treatment
|
To evaluate potential correlations between biomarkers HIF-1a, TSP-1, P53, VEGF, and VEGFR and use of the specified treatment regimen in the specified patient population
Časové okno: day 1 and end of treatment
|
day 1 and end of treatment
|
To evaluate progression free survival in the specified patient population
Časové okno: from the time of treatment start until progression or up to 5 years after completion of study treatment
|
from the time of treatment start until progression or up to 5 years after completion of study treatment
|
To assess quality of life as indicated by the Patient Care Monitor in the specified patient population
Časové okno: every 7 days during study treatment
|
every 7 days during study treatment
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Spolupracovníci
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. prosince 2009
Primární dokončení (Očekávaný)
1. prosince 2010
Dokončení studie (Očekávaný)
1. prosince 2010
Termíny zápisu do studia
První předloženo
27. srpna 2009
První předloženo, které splnilo kritéria kontroly kvality
27. srpna 2009
První zveřejněno (Odhad)
28. srpna 2009
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
14. února 2014
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
13. února 2014
Naposledy ověřeno
1. února 2014
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- ATDTCC0801
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na RAD001
-
Novartis PharmaceuticalsDokončenoMetastatický renální buněčný karcinom (mRCC)Německo
-
Children's Hospital Medical Center, CincinnatiNovartisDokončenoTuberózní skleróza | AngiolipomSpojené státy
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Children's Hospital of Philadelphia; Washington... a další spolupracovníciDokončeno
-
Novartis PharmaceuticalsDokončeno
-
Novartis PharmaceuticalsDokončenoLymfangioleiomyomatóza (LAM) | Komplex tuberózní sklerózy (TSC)Spojené státy, Spojené království, Německo, Itálie, Ruská Federace, Holandsko, Japonsko, Kanada, Polsko, Francie, Španělsko
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyDokončenoNádory mozku a centrálního nervového systémuSpojené státy, Izrael, Kanada
-
Guangdong Provincial People's HospitalNovartisNeznámýNeuroendokrinní nádory | Karcinoidní nádorČína
-
Fox Chase Cancer CenterNáborMetastatický karcinom pankreatuSpojené státy
-
Novartis PharmaceuticalsUkončenoHepatocelulární karcinomSpojené státy, Španělsko, Korejská republika, Holandsko, Tchaj-wan
-
Anne Beaven, MDNovartisUkončenoDifuzní velkobuněčný B-lymfomSpojené státy